teaser
GlaxoSmithKline (GSK) is to work with Synta Pharmaceuticals on the development of a new skin cancer drug, in a deal which could be worth £493m.
Synta will fund the development of STA-4783, which is aimed at treating metastatic melanoma, the most deadly form of skin cancer.
The companies will jointly sell the drug in the USA and Synta will receive a share of the profits.
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
Synta said the drug worked by overloading cancerous cells with oxygen, which effectively makes them self-destruct. Non-cancerous cells have a much higher tolerance for oxygen, and so are unaffected by the medication.
Currently there are very few drugs on the market for people with advanced skin cancer, which kills 70% of sufferers within one year.
